Creatine is best known as a sports supplement, used by athletes and gym-goers to support short bursts of high-intensity exercise.
Now, researchers are exploring a different potential use. Whether it could help some people with major depressive disorder when added to standard treatment.
A systematic review published in Brain Medicine examined the available clinical-trial evidence on creatine monohydrate and mental health. The findings offer a reason for further research, not a reason to view creatine as a replacement for established depression care.
The review suggests that creatine may improve depressive symptoms for some people with major depressive disorder, particularly when used alongside antidepressant medication or psychological therapy.
Yet results varied considerably between studies. Several trials found benefits. Others found little difference from placebo. The research base is small, involving only five randomised controlled trials and 238 participants in total.
That distinction matters. Creatine is not a proven treatment for depression. It may become a useful additional option for selected patients, though much larger and longer studies are needed before clinicians can know who is most likely to benefit.
Major depressive disorder, often called clinical depression, is more than a temporary period of sadness or stress. It is a medical condition that can involve persistent low mood, loss of interest or pleasure, sleep changes, fatigue, poor concentration, feelings of worthlessness and, for some people, thoughts of self-harm or suicide. Treatment commonly includes talking therapies, antidepressant medicines, or both.
These treatments can be highly effective, but not everyone improves fully. Some people have only a partial response to an antidepressant. Others experience side effects, struggle to access therapy, or need several treatment approaches before finding one that helps. That unmet need has encouraged scientists to investigate whether existing medicines, nutritional approaches and supplements might support standard care.
Creatine has drawn interest because of its role in cellular energy. The body makes creatine naturally, and it is also found in foods such as red meat and fish. Creatine is stored in muscles and other tissues, including the brain, where it helps maintain supplies of energy during periods of increased demand.
Brain cells require a constant energy supply to communicate, regulate chemical signals and carry out basic functions. Researchers have linked depression with changes in energy metabolism and mitochondrial function. Mitochondria are often described as the energy-producing structures within cells. This does not mean that depression has a single cause or that reduced cellular energy explains every case. Depression is a complex condition shaped by biological, psychological, social and environmental factors.
Still, the energy hypothesis is biologically plausible. Creatine may act as an energy buffer, helping cells rapidly regenerate adenosine triphosphate, or ATP, the molecule that supplies energy for many cellular processes. Scientists are also studying whether creatine could affect pathways involved in dopamine and serotonin signalling. These possible mechanisms remain under investigation. They should not be mistaken for proof that creatine works as an antidepressant.
Researchers reviewed randomised controlled trials, the type of study designed to compare an intervention against a placebo or another treatment. The review focused mainly on mood disorders. Participants received either creatine supplementation or a placebo, usually alongside existing depression treatment.
Across the five trials, 126 people received creatine and 112 received placebo. The average participant was 36 years old. Most participants were women, while two trials enrolled women only. Treatment periods generally lasted between four and eight weeks. Daily doses ranged from 2 grams to 10 grams.
The variation between studies was substantial. Participants differed in age, diagnosis and previous treatment response. Studies also used different creatine doses, treatment durations and approaches to care. Some paired creatine with an antidepressant. Another assessed it alongside cognitive behavioural therapy, commonly known as CBT. Because these differences made direct comparisons difficult, the researchers did not conduct a statistical meta-analysis. Instead, they summarised the findings in narrative form.
Some results were encouraging. Two reports based on the same clinical trial found that women with major depressive disorder taking 5 grams of creatine monohydrate daily alongside the antidepressant escitalopram (Lexapro) had greater improvement in depressive symptoms than women receiving escitalopram with placebo. After eight weeks, participants in the creatine group were also more likely to reach remission, meaning their symptoms had improved to a level below the study’s threshold for active depression.
Another trial found that participants receiving creatine alongside CBT experienced greater reductions in symptoms than those receiving CBT with placebo. These findings suggest creatine may have potential as an adjunctive treatment, meaning an addition to care that is already underway.
However, the positive results did not appear consistently.
One trial involving people whose depression had not improved with antidepressant treatment found that adding creatine did not significantly reduce symptoms after four weeks. A study in teenage girls with depression found no meaningful advantage for several creatine doses compared with placebo after eight weeks. This is especially important for families: a small trial in adolescents is not evidence that creatine should be used routinely by young people with depression.
The review also included a study involving people with bipolar disorder. It found no clear benefit from creatine. Two people in the creatine group developed hypomania or mania during the trial. The study cannot establish with certainty that creatine caused those episodes. Even so, the finding is an important warning signal.
Bipolar disorder is different from unipolar major depression. It involves episodes of depression as well as periods of unusually elevated, irritable or energised mood. Symptoms of mania or hypomania can include sleeping less without feeling tired, racing thoughts, unusually rapid speech, impulsive behaviour, increased activity and a heightened sense of confidence or agitation. People with bipolar disorder should not start creatine for mood symptoms without discussing it with a psychiatrist or another qualified clinician.
For healthy adults, creatine monohydrate has generally been well tolerated in research when taken as directed. In the depression studies reviewed, reported side effects were mostly mild digestive problems. Nevertheless, “generally safe” does not mean suitable for every person or every situation.
People with kidney disease, a history of bipolar disorder, complex medical conditions or multiple medicines should speak to a healthcare professional before using creatine. People who are pregnant, breastfeeding or considering supplements for a child should also seek individual clinical advice. Existing studies are too small to answer all safety questions across these groups.
It is also important to remember that supplements are not equivalent to prescription medicines. Product quality and labelling can differ between brands and markets. Consumers who decide to discuss creatine with a clinician may wish to ask about choosing plain creatine monohydrate from a reputable manufacturer, as this is the form used most often in research. Taking higher amounts is not necessarily better. Larger doses have not consistently produced better mental-health outcomes.
For someone already being treated for depression, creatine should not prompt them to stop medication or abandon therapy. Sudden changes to treatment can worsen symptoms or lead to withdrawal effects. The safest approach is to treat creatine, if it is considered at all, as a possible supplement to an evidence-based care plan rather than an alternative to one.
The review’s limitations should temper public expectations. Five small trials cannot settle a clinical question of this size. The studies included relatively few men, few older adults and limited demographic diversity. Researchers do not yet know whether effects might differ by sex, age, diet, depression severity, medication type or underlying biology. Animal research has suggested that creatine’s effects may vary between males and females, though this has not been clearly established in people with depression.
There were also no qualifying trials in the review for mental-health conditions outside mood disorders. That means there is currently no solid basis for claiming that creatine treats anxiety disorders, psychosis, attention problems or general stress.
The most responsible conclusion is cautiously hopeful. Creatine is inexpensive, widely available and has a comparatively reassuring safety record in healthy adults. Its role in brain energy metabolism gives researchers a credible reason to study it. A few trials suggest it could improve outcomes when paired with conventional depression treatment.
Yet the evidence remains preliminary and inconsistent. Creatine is not a miracle supplement, and it is not a substitute for professional assessment, prescribed treatment or urgent mental-health support.
People experiencing persistent low mood, loss of interest, hopelessness or major changes in sleep and appetite should speak with a healthcare professional. Anyone experiencing thoughts of self-harm or suicide should seek urgent local emergency or crisis support. People who develop agitation, markedly reduced need for sleep, unusually elevated mood or risky behaviour should also seek prompt medical advice, particularly if they have started or changed a supplement or medicine.
For now, the foundations of mental health remain familiar. Regular movement, adequate sleep, nutritious food, social support, stress management and treatment tailored to the individual can all matter. These measures may not resolve depression on their own, but they remain central to recovery and long-term wellbeing.
Creatine may eventually earn a place among the options that support depression treatment. The current evidence says it is worth attention and studying further. It does not yet say that everyone with depression should take it.
The post Early Evidence Shows Creatine Supplements May Help Depression first appeared on PP Health Malaysia.
